Effectiveness of pathogenetic therapy of insulin resistance in adolescent girls with menstrual cycle disorders
Abstract
Aim. To study clinical and metabolic characteristics in adolescent girls with MCD and IR and to evaluate the
effectiveness of complex pathogenetic therapy with metformin combined with non-pharmacological correction.
Material and methods. A prospective cohort study was conducted in 52 girls aged 15–18 years with MCD and BMI
≥25 kg/m², divided into two groups: with emerging polycystic ovary syndrome (PCOS, n=22) and with hypothalamic
syndrome of puberty (HSPP, n=30). The control group consisted of 14 healthy peers. All patients in the main groups
received metformin (1000–1500 mg/day), a hypocaloric diet (1000–1500 kcal/day) and aerobic exercise ≥150 min/week
for 6–9 months. Anthropometric, metabolic (glucose, insulin, HOMA-IR), hormonal parameters and restoration of
menstrual function were assessed before and after therapy.
Results. Initially, both groups showed significantly elevated BMI (thus in group 1 28,4±2.1 and in 2 group 31,2±3.0 kg/
m²), insulin (20,8±0.9 and 28,3±0.3 μIU/mL) and HOMA-IR (3,5±0,2 and 2,9±0,4) compared with controls (p<0,001). After
therapy, a significant decrease in BMI (Δ –1,6 and –2,1 kg/m²), insulin (Δ –4,3 and –6,9 μIU/mL) and HOMA-IR (Δ –0,8
and –0,7) was noted in both groups (p<0,05). Testosterone levels decreased in the PCOS group from 4,8±0.4 to 3,9±0,5
nmol/L (p<0,05). Regular menstrual cycles were restored in 54,5% of PCOS patients and in 60,0% of HSPP patients.
Conclusion. In adolescent girls with menstrual dysfunction due to insulin…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 30 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.